Tue-27-09-2016, 17:44 PM
There probably several reasons that are over my head. However, my guess is the maintenance dose is not enough. The further away you get from the loading dose or if you miss a dose the more problems you have.
AbbVie and Boehringer Ingelheim to develop and commercialize BI 655066
|
« Next Oldest | Next Newest »
|
Possibly Related Threads… | |||||
Thread | Author | Replies | Views | Last Post | |
Obese children more likely to develop psoriasis | Fred | 2 | 741 |
Thu-22-08-2024, 19:53 PM Last Post: Fred |
|
AbbVie will present data on risankizumab at EADV | Fred | 3 | 5,622 |
Mon-26-09-2016, 17:07 PM Last Post: jiml |
|
Psoriasis clear 66 months after one subcutaneous injection of trial drug BI 655066 | Fred | 11 | 16,238 |
Tue-08-03-2016, 19:10 PM Last Post: D Foster |
|
New psoriasis treatment BI 655066 worked faster than Stelara | Fred | 3 | 5,115 |
Thu-08-10-2015, 13:48 PM Last Post: jiml |
|
Queen Mary University to develop a targeted approach to psoriasis treatment | Fred | 18 | 26,272 |
Sat-30-11-2013, 12:05 PM Last Post: jiml |